OMER
OMEROS CORP
NASDAQ · Healthcare · Biotechnology · US
$18.17
−4.13%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +206.3%
- EBIT
- +47.4%
- EPS
- +190.5%
- Free cash flow
- +42.2%
- Operating cash flow
- +42.2%
Forward estimates
Based on analyst estimates
- Revenue
- +1254.8%
- EBITDA
- +274.9%
- EPS
- +70.4%
Three-year CAGR
- Revenue
- —
- EBITDA
- +98.8%
- EBIT
- +27.5%
- Net income
- +97.9%
- EPS
- +98.0%
- Free cash flow
- +22.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026